Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126300802 | 12630080 | 2 | F | 20160809 | 20160808 | 20160819 | EXP | US-PFIZER INC-2016374427 | PFIZER | HAROON, N.. HYPOMAGNESEMIA AND CHEMOTHERAPY, DIAGNOSTIC DILEMMA, AND TREATMENT CHALLENGE: CASE REPORT AND LITERATURE REVIEW. AMERICAN JOURNAL OF THERAPEUTICS. 2016;23(4):E1085-E1090 | 63.00 | YR | F | Y | 0.00000 | 20160819 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126300802 | 12630080 | 1 | SS | FLUOROURACIL. | FLUOROURACIL | 1 | UNK | U | 0 | ||||||||||
| 126300802 | 12630080 | 2 | SS | FLUOROURACIL. | FLUOROURACIL | 1 | 6 CYCLES | U | 0 | ||||||||||
| 126300802 | 12630080 | 3 | SS | FLUOROURACIL. | FLUOROURACIL | 1 | UNK | U | 0 | ||||||||||
| 126300802 | 12630080 | 4 | PS | IRINOTECAN HCL | IRINOTECAN HYDROCHLORIDE | 1 | UNK | U | 20571 | SOLUTION FOR INFUSION | |||||||||
| 126300802 | 12630080 | 5 | SS | IRINOTECAN HCL | IRINOTECAN HYDROCHLORIDE | 1 | UNK | U | 20571 | SOLUTION FOR INFUSION | |||||||||
| 126300802 | 12630080 | 6 | SS | IRINOTECAN HCL | IRINOTECAN HYDROCHLORIDE | 1 | 6 CYCLES | U | 20571 | SOLUTION FOR INFUSION | |||||||||
| 126300802 | 12630080 | 7 | SS | IRINOTECAN HCL | IRINOTECAN HYDROCHLORIDE | 1 | ONCE IN 2 WEEKS | U | 20571 | SOLUTION FOR INFUSION | |||||||||
| 126300802 | 12630080 | 8 | SS | IRINOTECAN HCL | IRINOTECAN HYDROCHLORIDE | 1 | ONCE IN 3 WEEKS | U | 20571 | SOLUTION FOR INFUSION | |||||||||
| 126300802 | 12630080 | 9 | SS | FOLINIC ACID | LEUCOVORIN | 1 | U | 0 | |||||||||||
| 126300802 | 12630080 | 10 | SS | FOLINIC ACID | LEUCOVORIN | 1 | UNK | U | 0 | ||||||||||
| 126300802 | 12630080 | 11 | SS | FOLINIC ACID | LEUCOVORIN | 1 | 6 CYCLES | U | 0 | ||||||||||
| 126300802 | 12630080 | 12 | SS | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | UNK | U | 0 | ||||||||||
| 126300802 | 12630080 | 13 | SS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | UNK | U | 0 | ||||||||||
| 126300802 | 12630080 | 14 | SS | XELODA | CAPECITABINE | 1 | UNK | U | 0 | ||||||||||
| 126300802 | 12630080 | 15 | SS | AVASTIN | BEVACIZUMAB | 1 | UNK | U | 0 | ||||||||||
| 126300802 | 12630080 | 16 | SS | AVASTIN | BEVACIZUMAB | 1 | UNK | U | 0 | ||||||||||
| 126300802 | 12630080 | 17 | SS | AVASTIN | BEVACIZUMAB | 1 | UNK | U | 0 | ||||||||||
| 126300802 | 12630080 | 18 | C | VITAMIN D | CHOLECALCIFEROL | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 19 | C | METOPROLOL. | METOPROLOL | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 20 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 21 | C | HYDROCODONE | HYDROCODONE | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 22 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 23 | C | CELECOXIB. | CELECOXIB | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 24 | C | LORAZEPAM. | LORAZEPAM | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 25 | C | MECLIZINE | MECLIZINE HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 26 | C | ZOLPIDEM | ZOLPIDEMOLPIDEM TARTRATE | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 27 | C | AMITRIPTYLINE | AMITRIPTYLINE | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 28 | C | ZANTAC | RANITIDINE HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 29 | C | BENADRYL | DIPHENHYDRAMINE HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 126300802 | 12630080 | 30 | C | ZOFRAN | ONDANSETRON HYDROCHLORIDE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126300802 | 12630080 | 1 | Retroperitoneal cancer |
| 126300802 | 12630080 | 4 | Adenocarcinoma of appendix |
| 126300802 | 12630080 | 5 | Retroperitoneal cancer |
| 126300802 | 12630080 | 6 | Metastases to peritoneum |
| 126300802 | 12630080 | 9 | Adenocarcinoma of appendix |
| 126300802 | 12630080 | 10 | Retroperitoneal cancer |
| 126300802 | 12630080 | 11 | Metastases to peritoneum |
| 126300802 | 12630080 | 14 | Retroperitoneal cancer |
| 126300802 | 12630080 | 15 | Adenocarcinoma of appendix |
| 126300802 | 12630080 | 16 | Retroperitoneal cancer |
| 126300802 | 12630080 | 17 | Metastases to peritoneum |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126300802 | 12630080 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126300802 | 12630080 | Diarrhoea | |
| 126300802 | 12630080 | Hypomagnesaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126300802 | 12630080 | 1 | 201005 | 0 | ||
| 126300802 | 12630080 | 2 | 201105 | 0 | ||
| 126300802 | 12630080 | 3 | 2007 | 0 | ||
| 126300802 | 12630080 | 4 | 2007 | 0 | ||
| 126300802 | 12630080 | 5 | 201005 | 0 | ||
| 126300802 | 12630080 | 6 | 201105 | 0 | ||
| 126300802 | 12630080 | 9 | 2007 | 0 | ||
| 126300802 | 12630080 | 10 | 201005 | 0 | ||
| 126300802 | 12630080 | 11 | 201105 | 0 | ||
| 126300802 | 12630080 | 15 | 2007 | 0 | ||
| 126300802 | 12630080 | 16 | 201005 | 0 | ||
| 126300802 | 12630080 | 17 | 201210 | 0 |